Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis (Q36072192)

12 August 2017

0 references

Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Haruhiko Nakamura

1

1 reference

12 August 2017

Norihito Kawasaki

series ordinal

2

1 reference

12 August 2017

Masahiko Taguchi

series ordinal

3

1 reference

12 August 2017

Kazuyuki Kabasawa

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

103

1 reference

12 August 2017

1865-1873

1 reference

12 August 2017

9

1 reference

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

12 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Prognostic value of the quantified expression of p185 in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Gefitinib (Iressa) trials in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Do molecular markers predict survival in non-small-cell lung cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Molecular biologic substaging of stage I lung cancer according to gender and histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

A biological staging model for operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Study of prognostic predictors for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Effect of HER2/neu expression on survival in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Publication Bias: A Problem in Interpreting Medical Data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Publishing negative data: beta-tubulin mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Language bias in randomised controlled trials published in English and German.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20957

7 January 2021

Identifiers

DOI

10.1002/CNCR.20957

1 reference

12 August 2017

1 reference